Chinese Journal of Integrative Medicine

, Volume 17, Issue 7, pp 492–498 | Cite as

A randomized double-blind placebo-controlled study of Pu’er tea (普洱茶) extract on the regulation of metabolic syndrome

  • Song-ling Chu (褚松龄)
  • Hong Fu (富 宏)
  • Jin-xia Yang (杨金霞)
  • Geng-xin Liu (刘庚信)
  • Pan Dou (窦 攀)
  • Liang Zhang (张 良)
  • Peng-fei Tu (屠鹏飞)
  • Xue-mei Wang (王学美)Email author
Original Article



To explore the regulative efficacy of Pu’er tea (普洱茶) extract on metabolic syndrome.


Ninety patients with metabolic syndrome were randomly divided into two groups, the intervention group administered with Pu’er tea extract, and the placebo group with placebo capsules. After 3 months’ treatment, body mass index, waist hip ratio, blood lipids, blood sugar, immune and inflammatory index, and oxidation index of the patients with metabolic syndrome were tested and analyzed.


In the intervention group, the body mass index, waist-hip ratio, fasting and 2 h postprandial blood glucose, serum total cholesterol, triglycerides, low density lipoprotein and apolipoprotein B-100 all decreased in the patients with metabolic syndrome, and also the high-density lipoprotein level increased and apolipoprotein A-1 showed the tendency to increase. Serum C-reactive protein, tumor necrosis factor-α, and interleukin-6 were decreased in the intervention group. Interleukin-10 level was increased, MDA was decreased and superoxide dismutase was increased. Compared with before treatment and the placebo group, there were significant differences (P<0.05, P<0.01).


Pu’er tea demonstrated excellent potential in improving central obesity, adjusting blood lipid, lowering blood sugar, regulating immunity and resisting oxidation. It can adjust the metabolic syndrome of different clinical phenotypes to different degrees, and is ideally fit for early prevention of metabolic syndrome.


tea metabolic syndrome randomized controlled clinical study 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wang PS, Liang MZ. Foretime and now of Pu’er tea. Tropical Agricultural Sci Technol (Chin) 2001;24(4):23–27.Google Scholar
  2. 2.
    Metabolic Syndrome Study Group of Diabetes Branch of Chinese Medical Association. Recommendations on the metabolic syndrome of Diabetes Branch of Chinese Medical Association. Chin J Diabetes (Chin) 2004;12:156–160.Google Scholar
  3. 3.
    Eckle RH, Grundy SM, Zimmet PZ. The metabolism syndrome. Lancet 2005;365:1415–1428.CrossRefGoogle Scholar
  4. 4.
    Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, et al. Prevalence of the metabolism syndrome and overweight among adult in China. Lancet 2005;365:1398–1405.PubMedCrossRefGoogle Scholar
  5. 5.
    Xiao YX. Recognition and therapeutic thoughts on metabolism syndrome. Chin J Basic Med Tradit Chin Med (Chin) 2007;13:538–539.Google Scholar
  6. 6.
    Li XJ, Liu ZL. Discussion on treatment of metabolism syndrome from spleen. Guiding J Tradit Chin Med Pharmacol (Chin) 2006;12(4): 9–10.Google Scholar
  7. 7.
    Yuan HB, Zhong J, Yi J, Zhao Y, Cao J. Tea extract on diet-induced obese rats lipogenic gene expression. Acta Nutrimenta Sin (Chin) 2009;31:167–171.Google Scholar
  8. 8.
    Jiang XF, Shao WF, Hou Y. Study on the function of preventing the hyperlipidemia lipid level and the antioxidant of the Pu’er tea. J Yunnan Agricultural Univ (Chin) 2009;24:705–711.Google Scholar
  9. 9.
    Zhou BX, Kong LB, Chen JX. Study on extraction of Pu’er tea polysaccharides and hypoglycemic. Chin Agricultural Sci Bull (Chin) 2009;25(15):55–59.Google Scholar
  10. 10.
    Wellen KE, Hotamisliglil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785–1788.PubMedGoogle Scholar
  11. 11.
    Cardoso-Saldaña G, Juárez-Rojas JG, Zamora-González J, Raygoza-Pérez M, Martinez-Alvarado R, Posadas-Sánchez R, et al C-reactive protein levels and their relationship with metabolic syndrome and insulin resistance in Mexican adolescents. J Pediatr Endocrinol Metab 2007;20:797–805.PubMedCrossRefGoogle Scholar
  12. 12.
    Kraja AT, Province MA, Arnett D, Wagenknecht L, Tang WH, Hopkins PN, et al. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster. Nutr Metab (Lond) 2007;4:28.CrossRefGoogle Scholar
  13. 13.
    Ferrari R, Ceconi C, Curello S, Cargnoni A, Alfieri O, Pardini A, et al. Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am J Med 1991;91(3C):95S–105S.CrossRefGoogle Scholar
  14. 14.
    Hatori N, Sjöquist PO, Marklund SL, Pehrsson SK, Rydén L. Effects of recombinant human extracellular-superoxide dismutase type C on myocardial reperfusion injury in isolated cold-arrested rat hearts. Free Radic Biol Med 1992;13:137–142.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract 2001; 54(Suppl 2):S29–S33.PubMedCrossRefGoogle Scholar
  16. 16.
    Yang AF, Liu MY, Wang CQ, Ding HY, Xie XL, Xu YM, et al. Metabolic syndrome patients with oxidation — index changes of platelet aggregation. J Cardiovas Pulmonary Dis (Chin) 2004;23:228–230.Google Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Song-ling Chu (褚松龄)
    • 1
  • Hong Fu (富 宏)
    • 1
  • Jin-xia Yang (杨金霞)
    • 1
  • Geng-xin Liu (刘庚信)
    • 1
  • Pan Dou (窦 攀)
    • 1
  • Liang Zhang (张 良)
    • 2
  • Peng-fei Tu (屠鹏飞)
    • 2
  • Xue-mei Wang (王学美)
    • 1
    Email author
  1. 1.Integration of Chinese and Western Medicine Laboratory of the First Hospital, Graduate School of Integration of Chinese and Western MedicineBeijing Medical UniversityBeijingChina
  2. 2.State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical SciencesPeking UniversityBeijingChina

Personalised recommendations